-
Rationale and design of the HOVON 170 DLBCL-ANTICIPATE trial: preventing anthracycline-induced cardiac dysfunction with dexrazoxane
Linschoten, M., Geels, J., van Werkhoven, E., Visser-Wisselaar, H., Chamuleau, M. E. D., Teske, A. J., Robbers, L., Oerlemans, S., Crommelin, H., Breems-de Ridder, M., Schut, A., Asselbergs, F. W. & on behalf of the HOVON 170 DLBCL – ANTICIPATE consortium, 1 Dec 2025, In: Cardio-Oncology. 11, 1, 8.Research output: Contribution to journal › Article › Academic › peer-review
-
Heart failure in patients with acute myeloid leukemia (AML) treated with anthracycline agents during remission induction therapy: a systematic review and meta-analysis
Geels, J., van Rhenen, A., Gradowska, P., Asselbergs, F. W. & Linschoten, M., 2025, (E-pub ahead of print) In: Leukemia.Research output: Contribution to journal › Article › Academic › peer-review
-
Risk prediction models for cancer therapy related cardiac dysfunction in patients with cancer and cancer survivors: systematic review and meta-analysis
Gomes, C., Geels, J., Debray, T. P. A., Malekzadeh, A., Asselbergs, F. W. & Linschoten, M., 2025, In: BMJ. 390, e084062.Research output: Contribution to journal › Article › Academic › peer-review
- All publications
